Emergent BioSolutions (NYSE:EBS) Downgraded by StockNews.com to “Hold”

StockNews.com cut shares of Emergent BioSolutions (NYSE:EBS) from a buy rating to a hold rating in a research note published on Wednesday.

A number of other equities research analysts also recently weighed in on EBS. Benchmark lifted their target price on Emergent BioSolutions from $8.00 to $12.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Rodman & Renshaw restated a “buy” rating and set a $16.00 price objective on shares of Emergent BioSolutions in a research report on Friday, September 13th.

Emergent BioSolutions Price Performance

Shares of Emergent BioSolutions stock opened at $9.48 on Wednesday. The company has a debt-to-equity ratio of 1.30, a current ratio of 2.88 and a quick ratio of 1.47. The company has a market cap of $513.63 million, a PE ratio of -2.31 and a beta of 1.57. The firm has a fifty day moving average price of $8.79 and a two-hundred day moving average price of $8.22. Emergent BioSolutions has a fifty-two week low of $1.42 and a fifty-two week high of $15.10.

Institutional Trading of Emergent BioSolutions

Several institutional investors have recently made changes to their positions in the business. BNP Paribas Financial Markets boosted its holdings in Emergent BioSolutions by 155.3% during the first quarter. BNP Paribas Financial Markets now owns 163,589 shares of the biopharmaceutical company’s stock valued at $414,000 after purchasing an additional 99,520 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Emergent BioSolutions by 14.7% during the 1st quarter. Vanguard Group Inc. now owns 3,411,549 shares of the biopharmaceutical company’s stock worth $8,631,000 after buying an additional 436,911 shares during the period. Price T Rowe Associates Inc. MD boosted its stake in Emergent BioSolutions by 22.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 23,943 shares of the biopharmaceutical company’s stock valued at $61,000 after buying an additional 4,409 shares in the last quarter. Tidal Investments LLC acquired a new position in Emergent BioSolutions during the first quarter worth $34,000. Finally, Cetera Advisors LLC bought a new position in shares of Emergent BioSolutions during the first quarter valued at $428,000. 78.40% of the stock is currently owned by institutional investors and hedge funds.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.